Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
Tudor Investment Corp ET AL Takes Position in Pharvaris N.V. $PHVS
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
Pharvaris N.V. (NASDAQ:PHVS) Receives $41.70 Consensus Target Price from Brokerages
Pharvaris N.V. $PHVS Shares Purchased by General Atlantic L.P.
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of “Moderate Buy” from Brokerages
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest
Pharvaris Outlines 2026 Strategic Priorities
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now
Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating
Why Bain Capital Is Selling Shares of This Biotech Stock Now
Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume After Analyst Upgrade
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Pharvaris Announces Proposed Public Offering of Ordinary Shares
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
Pharvaris Announces Annual Meeting of Shareholders
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update